Ertapenem plus meropenem combination treatment in carbapenem-resistant Klebsiella pneumoniae bacteremia: an analysis of 53 cases

Eur J Clin Microbiol Infect Dis. 2023 Oct;42(10):1269-1273. doi: 10.1007/s10096-023-04660-3. Epub 2023 Sep 7.

Abstract

Herein, we aimed to describe the outcomes of patients with blood stream infections due to carbapenem-resistant Klebsiella pneumoniae (CR-Kp) who received ertapenem plus meropenem combination treatment (EMCT). A total of 53 patients with culture proven CR-Kp bacteremia treated with ertapenem + meropenem were included. The patients with secondary bacteremia due to urinary tract infection exhibited a significantly lower 1-month mortality (OMM), particularly in those with microbiological eradication and those with end-of-treatment success. Salvage EMCT resulted in 49% 1-month survival.

Keywords: Bacteremia; Carbapenem-resistant Klebsiella pneumonia; Double carbapenem therapy.

MeSH terms

  • Bacteremia* / drug therapy
  • Carbapenem-Resistant Enterobacteriaceae*
  • Ertapenem
  • Humans
  • Klebsiella pneumoniae
  • Meropenem / therapeutic use
  • Salvage Therapy

Substances

  • Ertapenem
  • Meropenem